Description: Bio-Thera Solutions, Ltd., commercial-stage biopharmaceutical company, researches and develops therapeutics for the treatment of cancer, autoimmune, cardiovascular, and other serious medical conditions. It offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; and POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, and metastatic cervical cancer. The company also develops BAT1806, a tocilizumab biosimilar candidate of Actemra/RoActemra, which is in Phase III clinical trial; BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn's disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406, BAT2606, and BAT2406 for treatment of various autoimmune diseases. In addition, it develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT6005, BAT6021, BAT7104, BAT8006, BAT8009, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; BAT5906 that is in Phase II clinical trial for the treatment for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions; and BAT2022 to treat infectious diseases. The company was founded in 2003 and is headquartered in Guangzhou, China.
Home Page: www.bio-thera.com
Building A6
Guangzhou,
510530
China
Phone:
86 20 3220 3220
Officers
| Name | Title |
|---|---|
| Mr. Shengfeng Li | Founder, CEO, GM & Director |
| Dr. Cui Hua Liu | Deputy GM & SVP of Technology Devel. |
| Dr. Jinchen Yu | Deputy GM, SVP of Preclinical Research & Director |
| Dr. Xianming Huang | SVP of Discovery Research & Director |
| Dr. Bert E. Thomas IV | Deputy GM & SVP of Bus. Devel. |
| Dr. Lan Mu | Deputy GM & SVP of Regulatory Affairs |
| Ms. Dan Yu | Exec. Director & Sec. to the Board |
| Ms. Wenrong Huang | Deputy Gen. Mang. |
Exchange: SHG
Country: CN : China
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 154.1053 |
| Price-to-Book MRQ: | 5.3092 |
| Price-to-Sales TTM: | 12.031 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 936 |